E-selectin

Mammalian protein found in Homo sapiens

E selectin, also known as CD62 antigen like family member E (CD62E), endothelial leukocyte adhesion molecule 1 (ELAM 1), or leukocyte endothelial cell adhesion molecule 2 (LECAM2), is a selectin cell adhesion molecule expressed only on endothelial cells activated by cytokines. Like other selectins, it plays an important part in inflammation. In humans, E selectin is encoded by the SELE gene.

E selectin has a cassette structure: an N terminal, C type lectin domain, an EGF (epidermal growth factor) like domain, 6 Sushi domain (SCR repeat) units, a transmembrane domain (TM) and an intracellular cytoplasmic tail (cyto). The three dimensional structure of the ligand binding region of human E selectin has been determined at 2.0 Å resolution in 1994. The structure reveals limited contact between the two domains and a coordination of Ca2+ not predicted from other C type lectins. Structure/function analysis indicates a defined region and specific amino acid side chains that may be involved in ligand binding. The E selectin bound to sialyl LewisX (SLeX; NeuNAcα2,3Galβ1,4[Fucα1,3]GlcNAc) tetrasaccharide was solved in 2000.

In humans, E selectin is encoded by the SELE gene. Its C type lectin domain, EGF like, SCR repeats, and transmembrane domains are each encoded by separate exons, whereas the E selectin cytosolic domain derives from two exons. The E selectin locus flanks the L selectin locus on chromosome 1. Different from P selectin, which is stored in vesicles called Weibel Palade bodies, E selectin is not stored in the cell and has to be transcribed, translated, and transported to the cell surface. The production of E selectin is stimulated by the expression of P selectin which in turn, is stimulated by tumor necrosis factor α (TNFα), interleukin 1 (IL 1) and lipopolysaccharide (LPS). It takes about two hours, after cytokine recognition, for E selectin to be expressed on the endothelial cell's surface. Maximal expression of E selectin occurs around 6–12 hours after cytokine stimulation, and levels returns to baseline within 24 hours. Phytoestrogens, plant compounds with estrogen like biological activity, such as genistein, formononetin, biochanin A and daidzein, as well as a mixture of these phytoestrogens were found able to reduce E selectin as well as VCAM 1 and ICAM 1 on cell surface and in culture supernatant.

E selectin recognizes and binds to sialylated carbohydrates present on the surface proteins of certain leukocytes. E selectin ligands are expressed by neutrophils, monocytes, eosinophils, memory effector T like lymphocytes, and natural killer cells. Each of these cell types is found in acute and chronic inflammatory sites in association with expression of E selectin, thus implicating E selectin in the recruitment of these cells to such inflammatory sites. These carbohydrates include members of the Lewis X and Lewis A families found on monocytes, granulocytes, and T lymphocytes. The glycoprotein ESL 1, present on neutrophils and myeloid cells, was the first counter receptor for E selectin to be described. It is a variant of the tyrosine kinase FGF glycoreceptor, raising the possibility that its binding to E selectin is involved in initiating signaling in the bound cells. P selectin glycoprotein ligand 1 (PSGL 1) derived from human neutrophils is also a high efficiency ligand for endothelium expressed E selectin under flow. It mediates the rolling of leukocytes on the activated endothelium surrounding an inflamed tissue. Both ESL 1 and PSGL 1 should bear sialyl Lewis a/x in order to bind E/P selectins. E selectin is found to mediate the adhesion of tumor cells to endothelial cells, by binding to E selectin ligands on the tumor cells. E selectin ligands also play a role in cancer metastasis. The role of these two E selectin ligands in metastasis in vivo is poorly defined and remains to be firmly demonstrated. PSGL 1 was detected on the surfaces of bone metastatic prostate tumor cells, suggesting that it may have a functional role in the bone tropism of prostate tumor cells. In cancer cells, CD44, death receptor 3 (DR3), LAMP1, and LAMP2 were identified as E selectin ligands present on colon cancer cells, and CD44v, Mac2 BP, and gangliosides were identified as E selectin ligands present on breast cancer cells. On human neutrophils the glycosphingolipid NeuAcα2 3Galβ1 4GlcNAcβ1 3[Galβ1 4(Fucα1 3)GlcNAcβ1 3]2[Galβ1 4GlcNAcβ1 3]2Galβ1 4GlcβCer (and closely related structures) are functional E selectin receptors.

During inflammation, E selectin plays an important part in recruiting leukocytes to the site of injury. The local release of cytokines IL 1 and TNF α by macrophages in the inflamed tissue induces the over expression of E selectin on endothelial cells of nearby blood vessels. Leukocytes in the blood expressing the correct ligand will bind with low affinity to E selectin, also under the shear stress of blood flow, causing the leukocytes to "roll" along the internal surface of the blood vessel as temporary interactions are made and broken. As the inflammatory response progresses, chemokines released by injured tissue enter the blood vessels and activate the rolling leukocytes, which are now able to tightly bind to the endothelial surface and begin making their way into the tissue. This led to the hypothesis that cancer cells secreted inflammatory cytokines such as IL 1β or TNFα to induce E selectin at distant metastatic sites. This induction would enable circulating tumor cells to arrest at stimulated sites, roll along activated endothelium, extravasate, and form metastases. Studies since have showed that E selectin binding to colon cancer cells correlates with increasing metastatic potential, and that cancer cells of multiple tumor types bind E selectin using glycoprotein or glycolipid ligands normally expressed on immune cells. Studies have further described a mechanistic cascade wherein cancer cells first bind E selectin at shear flow rates: E selectin binding results in a velcro like interaction allowing the cancer cells to engage higher affinity integrin binding that eventually results in a tight binding between tumor cells and the activated endothelium. While numerous pieces of in vitro and clinical evidence continue to support this hypothesis of E selectin mediated cancer metastasis, in vivo studies of cancer metastasis have shown that E selectin knockout only minimally affects leukemic cell adhesion to bone immediately following injection. while experimental lung metastasis is not affected by the genetic deletion of E selectin. Furthermore, studies have also shown that primary tumor growth is increased in E selectin knockout mice. This paradox was more recently solved by a trio of studies showing that E selectin is only constitutively expressed in the bone marrow endothelium where it is thought to perform functions vital to hematopoiesis. that are hijacked specifically by cells metastasizing to bone and not other sites. This data supports ongoing clinical efforts to inhibit breast cancer bone metastasis with E selectin blocking agents. The complexity of E selectin ligand biology may also play a role in these discrepant in vitro and in vivo results. At least 15 different glycoprotein and glycolipid substrates for E selectin have been described on various cancer cells, while only n glycan Glg1 (Esl1) was shown to mediate bone metastasis. Other ligands or combinations thereof may result in distinct mechanisms during cancer metastasis. Beyond a direct interaction with tumor cells, E selectin induction in response to cytokines locally secreted by cancer cells enables specific tumor targeting of sLeX conjugated nanoparticles or thioaptamers containing anti tumor payloads. In addition, E selectin may also function to recruit monocytes to primary tumors or lung metastases to promote an inflammatory pro tumor microenvironment. Blocking these interactions or enabling trafficking of CAR T cells to E selectin positive sites may hold promise for future therapeutic development.

In cases of elevated blood glucose levels, such as in sepsis, E selectin expression is higher than normal, resulting in greater microvascular permeability. The greater permeability leads to edema (swelling) of the skeletal endothelium (blood vessel linings), resulting in skeletal muscle ischemia (restricted blood supply) and eventually necrosis (cell death). This underlying pathology is the cause of the symptomatic disease critical illness polyneuromyopathy (CIPNM). Traditional Chinese herbal medicines, like berberine downregulate E selectin.

Study shows the adherence of Porphyromonas gingivalis to human umbilical vein endothelial cells increases with the induction of E selectin expression by TNF α. An antibody to E selectin and sialyl LewisX suppressed P. gingivalis adherence to stimulated HUVECs. P. gingivalis mutants lacking OmpA like proteins Pgm6/7 had reduced adherence to stimulated HUVECs, but fimbriae deficient mutants were not affected. E selecin mediated P. gingivalis adherence activated endothelial exocytosis. These results suggest that the interaction between host E selectin and pathogen Pgm6/7 mediates P. gingivalis adherence to endothelial cells and may trigger vascular inflammation.

The immunohistochemical expressions of E selectin and PECAM 1 were significantly increased at intima in vulnerable plaques of acute coronary syndrome (ACS) group, especially in neovascular endothelial cells, and positively correlated with inflammatory cell density, suggesting that PECAM 1 and E selectin might play an important role in inflammatory reaction and development of vulnerable plaque. E selectin Ser128Arg polymorphism is associated with ACS, and it might be a risk factor for ACS.

Smoking is highly correlated with enhanced likelihood of atherosclerosis by inducing endothelial dysfunction. In endothelial cells, various cell adhesion molecules including E selectin, are shown to be upregulated upon exposure to nicotine, the addictive component of tobacco smoke. Nicotine stimulated adhesion of monocytes to endothelial cells is dependent on the activation of α7 nAChRs, β Arr1 and cSrc regulated increase in E2F1 mediated transcription of E selectin gene. Therefore, agents such as RRD 251 that can target activity of E2F1 may have potential therapeutic benefit against cigarette smoke induced atherosclerosis.

It's also found that E selectin expression increased in human ruptured cerebral aneurysm tissues. E selectin might be an important factor involved in the process of cerebral aneurysm formation and rupture, by promoting inflammation and weakening cerebral artery walls.

E selectin is also an emerging biomarker for the metastatic potential of some cancers including colorectal cancer and recurrences.